QNTM gets FDA approval and also an earnings beat. This should run

On August 14, 2026, Quantum BioPharma Ltd. filed a Form 6-K with the SEC, providing its financial and operational results for the second quarter ended June 30, 2026. The company reported a strengthened balance sheet, with combined cash, cash equivalents, and digital assets totaling approximately US$9.5 million, up from US$4.1 million at the end of 2025. Specifically, cash and cash equivalents nearly doubled to US$3.65 million. Management noted a disciplined reduction in costs, with total operating expenses falling 53% year-over-year to US$2.29 million, and cash used in operating activities decreasing 44% to US$3.46 million for the first half of 2026. Based on these metrics, the company projects sufficient liquidity to fund operations through at least October 2027. Operationally, the filing highlights a significant regulatory milestone: on August 10, 2026, the FDA approved the company’s Investigational New Drug application for Lucid-MS, allowing the firm to initiate a Phase 2 clinical trial for progressive multiple sclerosis. The submission includes a press release as Exhibit 99.1 detailing these financial improvements and the advancement of its neuroprotective clinical program.